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Natural productsa b s t r a c t
The enediyne natural products have been explored for their phenomenal cytotoxicity. The development
of enediynes into anticancer drugs has been successfully achieved through the utilization of polymer- and
antibody–drug conjugates (ADCs) as drug delivery systems. An increasing inventory of enediynes would
beneﬁt current application of ADCs in many oncology programs. Innovations in expanding the enediyne
inventory should take advantage of the current knowledge of enediyne biosynthesis and post-genomics
technologies. Bioinformatics analysis of microbial genomes reveals that enediynes are underexplored, in
particular from Actinomycetales. This digest highlights the emerging opportunities to explore microbial
genomics for the discovery of novel enediyne natural products.
 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).The enediyne natural products are the most cytotoxic molecules
in existence today, and their use as anticancer drugs has been dem-
onstrated clinically.1–6 The natural enediynes have seen limited
use as clinical drugs mainly because of substantial toxicity, how-
ever, various polymer-based delivery systems or antibody–drug
conjugates (ADCs) have shown great clinical success or promise
in anticancer therapy.7–12 Indeed, the poly(styrene-co-maleic
acid)-conjugated neocarzinostatin (SMANCS) has been marketed
since 1994 for use against hepatoma.2 Various ADCs have been
developed or are in varying stages of development, including a
CD33 mAB-calicheamicin (CAL) conjugate (i.e., Mylotarg) for
acute myeloid leukemia (AML), a CD22 mAB-CAL conjugate
(inotuzumab ozogamicin) for non-Hodgkin lymphoma,10,11 as well
as, several mAB-C-1027 conjugates for hepatoma3,13 and
mAB-uncialamycin (UCM) conjugates for selected tumors.14 (Pﬁzer
voluntarily withdrew Mylotarg from the market in 2010;
however, signiﬁcant survival beneﬁts observed in recent phase III
trials suggest that Mylotarg may have an important future role
in treating patients with good- or intermediate-risk AML.15) These
examples clearly demonstrate that the enediynes can be developed
into powerful drugs when their extremely potent cytotoxicity isharnessed and delivered to tumor cells. It is remarkable that
among the 11 enediynes known to date, two, neocarzinostatin
(NCS) and CAL, have been developed into clinical drugs and one,
C-1027, is in clinical trials, representing an astonishing 30%
success rate with the enediyne class of natural products (Fig. 1).
Developing innovative methods to discover new enediynes there-
fore holds a great promise for anticancer drug discovery.
Inspired by the recent success of two ADCs (Adcetris in 2011
and Kadcyla in 2013), interests in anticancer ADCs continue to
grow, and virtually every major pharmaceutical company with an
oncology program now has an initiative on ADCs.9–11 Among the
30+ ADCs currently in development, however, the majority of them
use one of the few available cytotoxic drugs (auristatin, CAL,
maytansinoid, doxorubicin, camptothecin, duocarmycin, and
C-1027), all of which are of natural product origin.9–11 The ADC
ﬁeld is in critical need of new, highly potent cytotoxic payloads
(IC50s at 1 nM–10 pM), active in many tumor types, with improved
physical, chemical, and biological properties. Therefore, new
enediynes would be extremely valuable assets in the development
of safer, more effective ADCs with a validated mode of action. This
digest highlights the emerging opportunities to explore microbial
genomics for the discovery of novel enediyne natural products, in
particular, those from the Actinomycetales.
Enediyne discovery, structures, and activities. Enediyne natural
products are very rare. Since the NCS chromophore structure was
Figure 1. Structures of the 11 enediynes, (A) ﬁve nine-membered and (B) six 10-membered ones, known to date with the enediyne cores highlighted in red. The sporolides,
cyanosporasides, and ﬁjiolides were proposed to be derived from nine-membered enediyne precursors based on their chlorine substitution pattern after cycloaromatization.
Given in parentheses are the years when each of the enediyne structures was established. CAL and NCS have been developed into clinical drugs, C-1027 is currently in phase II
trials, and several analogues of UCM have been evaluated as ADC payloads in preclinical studies.
10 B. Shen et al. / Bioorg. Med. Chem. Lett. 25 (2015) 9–15ﬁrst elucidated in 1985,16 only 11 enediynes are structurally char-
acterized to date, with an additional four isolated in the cycloaro-
matized form (Fig. 1).17,18 Discovery of a new enediyne natural
product is therefore a signiﬁcant event in natural products chemis-
try, biology, and drug discovery.1–6 The enediyne natural products
are classiﬁed into two subcategories according to the size of the
enediyne cores. Members of the nine-membered enediynes are
commonly chromoproteins, consisting of an apoprotein and the
enediyne chromophore, including NCS from Streptomyces carzino-
staticus,16 C-1027 from Streptomyces globisporus,19 kedarcidin
(KED) from a Streptoalloteichus sp.,20 maduropeptin (MDP) from
Actinomadura madurae,21 N1999A2 from Streptomyces sp.
AJ9493,22 the sporolides (SPOs) from Salinispora tropica,23 the
cyanosporasides (CYAs) from Salinispora paciﬁca CNS-143,24 the
cyanosporasides (CYNs) Streptomyces sp. CNT-179,25 and the ﬁjio-
lides from Nocardiopsis sp. CNS-653,26 with the latter four isolatedin the absence of an apoprotein. 10-Membered enediynes are dis-
crete small molecules, including the CALs from Micromonospora
echinospora,27 dynemicin (DYN) from Micromonospora chersina,28
the esperamicins (ESPs) from Actinomadura verrucosospora,29
namenamicin from Polysyncraton lithostrotum,30 and UCM from
Streptomyces uncialis.31
While members of the enediyne family of natural products
exhibit remarkable structural diversities, all enediynes contain a
core consisting of two acetylenic groups conjugated to a double
bond or incipient double bond within the nine- or 10-membered
carbocycle (Fig. 1). As a consequence of this structural feature,
these compounds share a common mode of action. Electronic rear-
rangement (Bergman or Myers-Saito rearrangement) of the ened-
iyne carbocycle produces a transient benzenoid diradical.1–6
When positioned within the minor groove of DNA, the diradical
abstracts hydrogen atoms from the deoxyribose backbone of
B. Shen et al. / Bioorg. Med. Chem. Lett. 25 (2015) 9–15 11duplex DNA; the DNA-centered radicals can then cause interstrand
crosslinks (ICLs), react with molecular oxygen leading ultimately to
DNA double-strand breaks (DSBs), or both, resulting in the
phenomenal cytotoxicity known for the enediynes.4–6,17,18,30,31
Enediynes as payload candidates for anticancer ADCs. ADCs pro-
vide the possibility of selectively ablating cancer cells by combin-
ing the speciﬁcity of a mAB for a target antigen with the delivery
of a highly potent cytotoxic agent.7–12 The ideal number of drug
molecules per mAB for most current ADCs appears to be about
four.12 Underconjugation can decrease potency of the resultant
ADCs, whereas overconjugation can lead to decreased circulation
half-life, reduced tolerability, and impaired antigen binding.12
The preferred payload molecules therefore have to be highly
cytotoxic (IC50s at 1 nM–10 pM) and ideally active in many tumor
types. The enediynes represent some of the most cytotoxic
molecules in existence today (for example, the IC50s of CAL and
C-1027 towards selected cancer cell lines are in the range of
10 pM–103 pM).1–6,30,31 While the enediynes are mostly known
for their activity through DNA DSBs, ICL is an alternative mode of
action.30–33 The ICL property of the enediynes can be exploited to
target solid tumors or other cancer cells under hypoxic environ-
ments, which do not respond well to enediynes that predomi-
nantly induce oxygen-dependent DSBs.32,33 The exquisite potency
and mechanisms of action of the enediynes make them ideal
payload candidates for ADCs. The utilities of enediynes as payloads
of anticancer ADCs have been demonstrated in clinical therapy.7–12
Enediyne biosynthesis and engineering. The enediyne natural
products present an outstanding opportunity to (i) decipher the
genetic and biochemical basis for the biosynthesis of complexFigure 2. Characterization of the selected nine- and 10-membered enediyne biosynthetic
new enediyne natural products. (A) Alignment of the 10 known enediyne biosynthetic ge
common to all enediynes and varying open reading frames (color-coded) for the divers
uniﬁed model for enediyne core biosynthesis, featuring the production of heptaene by PK
between PKS-TE and nine- or 10-membered speciﬁc associated enzymes differentiatingnatural products,17,18 (ii) explore ways to make novel analogues
by manipulating genes governing their biosynthesis,30,31,34–36 and
(iii) discover new enediyne natural products by mining microbial
genomes for the trademark enediyne biosynthetic machiner-
ies.37,38 Signiﬁcant progress has been made in enediyne biosynthe-
sis and engineering in the last decade. Highlights include: (i)
cloning and characterization of the C-1027,39 NCS,40 MDP,41
KED,42 SPO,43 CYA and CYN25 biosynthetic gene clusters as exam-
ples of nine-membered enediyne natural products, (ii) cloning
and characterization of the CAL,44 ESP (partial),37,38 and DYN45 bio-
synthetic gene clusters as examples of 10-membered enediyne
natural products (Fig. 2A), (iii) establishment of the polyketide
origin for all enediynes and discovery of the enediyne PKS as an
acyl carrier protein (ACP)-dependent, self-phosphopantetheinylat-
ing, iteratively acting, type I polyketide synthase (PKS) that
produces a linear polyene to initiate both nine- and 10-membered
enediyne core biosynthesis (Fig. 2B),46,47 (iv) characterization of
numerous enzymes from the enediyne biosynthetic machineries
that catalyze novel chemistries,17,18 (v) engineered production of
novel enediyne analogues with altered modes of action,30,31 and
exploitation of the ICL property of the enediynes to target solid
tumors or other cancer cells under hypoxic environments,32,33
(vi) manipulation of the enediyne biosynthetic machinery for titer
improvement and production of selected enediynes in sufﬁcient
quantities to support further mechanistic studies and preclinical
development,35,36 (vii) development of methodologies to screen
microorganisms for the discovery of new enediyne natural prod-
ucts,37,38 and (viii) discovery that, in spite of the fact that only 11
enediyne natural products (14 if including the ones isolated inmachinery laying the foundation to explore microbial genomics for the discovery of
ne clusters, highlighting the enediyne PKS gene cassettes (i.e., E10, E, E5, E4, and E3)
e peripheral moieties, as well as for pathway regulation and self-resistance. (B) A
S and TE in the absence of associated enzymes (path a), and functional interactions
nine- (path b) or 10-membered (path c) core biosynthesis.
12 B. Shen et al. / Bioorg. Med. Chem. Lett. 25 (2015) 9–15the cycloaromatized form) have been isolated to date (Fig. 1), the
biosynthetic potential of Actinomycetales to produce enediynes
is greatly underappreciated.37,38 These ﬁndings have laid the foun-
dation to explore microbial genomics for the discovery of new
enediyne natural products. Thus, (i) genome survey of microbial
strain collections for the hallmark enediyne PKS gene cassettes
could allow rapid identiﬁcation of potential enediyne producers,
(ii) genome sequencing of the potential producers for the enediyne
biosynthetic gene clusters could allow accurate prediction of the
structural novelty of the new enediynes, and (iii) genetic manipu-
lation and fermentation optimization of the most promising pro-
ducers would ultimately allow efﬁcient production, isolation, and
structural and biological characterization of new enediyne natural
products.
Strain prioritization for novel natural product discovery. Tradi-
tional microbial natural product discovery programs begin by
fermenting each strain individually, often in various media,
followed by preparation of crude extracts. Two fundamental
methods to search for novel natural products from extracts are:
bioassay-guided fractionation and chemical proﬁling of com-
pounds possessing unique structural novelty.48,49 The desired mol-
ecule of interest must be produced in sufﬁcient amounts to
facilitate isolation and characterization on a reasonable timeframe.
The discovery of a new natural product typically requires three
principal steps: dereplication of known compounds to avoid
redundancies, isolation of the targeted molecules, and structural
elucidation of the puriﬁed natural products. Indeed, discovery of
the known enediynes relied mainly on bioassay-guided, extensive
natural product dereplication.16–31 The biochemical induction
assay (BIA) that detects DNA damaging agents was most com-
monly used to selectively assay for enediyne production and sub-
sequent isolation.37,50 While successful, only 14 enediyne natural
products are known to date. This tedious and laborious traditional
process could be signiﬁcantly shortened if the biosynthetic poten-
tial of a strain collection is known in advance. Resources could then
be devoted preferentially to only interrogate strains that hold the
highest promise in producing novel natural products, thereby
accelerating their discovery, isolation, and structural characterization.
Complementary to traditional approaches, the progress made in
the last two decades in connecting natural products to the genes
that encode their biosynthesis has fundamentally changed the
landscape of natural products research and sparked the emergence
of a suite of contemporary approaches to natural product
discovery.48,49,51–53 Thus, genes are now as important as chemistry
in categorizing known natural products and identifying new ones.
Advances in microbial genomics have unequivocally demonstrated
that we are missing 90% of the natural product biosynthetic
capacity of even the workhorse producers, the Actinobacteria.52,53
To access this untapped reservoir of potentially new natural
products, two principal strategies have been applied to induce
these ‘cryptic biosynthetic pathways’. The ‘epigenetic’-related
approaches include challenging the microorganisms through
culture conditions, nutritional or environmental factors, external
cues, and stress, as well as, exploiting interspecies crosstalk.54
The genomics-based approaches include mining the genomes
to predict metabolite structures, engineering the pathways by
manipulating pathway-speciﬁc or global regulators, and express-
ing the cryptic pathways in selected heterologous hosts.51–53,55
While each of the various approaches has different strengths and
weaknesses, they have been successful in yielding cryptic natural
products but only on a case-by-case basis and are far from being
of practical use for natural product discovery. Thus, in spite of
the rapid advances in DNA sequencing technologies and bioinfor-
matics, it is still impractical to sequence and annotate all strains
within a large collection as a practical means to discover new
natural products. High-throughput methods, rapidly surveyingthe biosynthetic potential of a strain collection so that strains that
harbor the highest biosynthetic potential can then be identiﬁed,
prioritized, and subjected to epigenetic- and/or genomics-based
approaches, could fundamentally change how natural products
are discovered.48,49
Enediyne PKS gene cassettes as a beacon for enediyne producers. In
spite of their remarkable structural diversity, the 14 known
enediyne natural products all feature a nine- or 10-membered
enediyne core (Fig. 1). Comparative bioinformatics analyses of
the seven nine- (NCS, C-1027, MDP, KED, SPO, CYA, and
CYN)25,39–43 and three 10-membered (CAL, DYN, and
ESP)37,38,44,45 enediyne PKS loci revealed a set of ﬁve genes
common to all enediynes (i.e., the enediyne PKS gene cassette
consisting of E10/E/E5/E4/E3) (Fig. 2A); no apparent conservation
was observed beyond the enediyne PKS gene cassettes, accounting
for the structural diversity characteristic for the periphery moieties
of the enediynes (Fig. 1). This remarkable sequence homology
has resulted in a uniﬁed model for the enediyne PKS cassette to
catalyze the formation of both nine- and 10-membered enediyne
cores. This model has been further supported by the fact that:
(i) PKS-TE (i.e., E–E10) catalyze the biosynthesis of heptaene as a
shunt metabolite (Fig. 2B) in the absence of the associated
enzymes,46,47 (ii) heptaene is co-produced in fermentations of
known enediyne producers, and (iii) heptaene production is
PKS-dependent—inactivation of the pksE gene abolished heptaene
production and complementation of the DpksE mutation with a
functional pksE restored its production.47 These observations
prompted us to select genes within the enediyne PKS cassettes as
probes to survey genomes for the presence of enediyne
biosynthetic machinery.37,38 Once the new enediyne producers
are identiﬁed, heptaene production, complementary to BIA for
enediyne production,37,50 could be used as a sensitive phenotypic
indicator to follow enediyne production upon fermentation
optimization.35,36,47
Actinomycetales as the most proliﬁc enediyne producers. It is now
clear that the biosynthetic potential of natural products is signiﬁ-
cantly underestimated based on the natural products isolated to
date.51–53 This is also true for the enediyne natural products,37,38
in spite of the fact that enediyne natural products are extremely
rare and only 14 enediyne natural products are known to date
(Fig. 1). A great challenge is to rapidly identify the most promising
enediyne producers, from a large strain collection, so that all
resources could be devoted to interrogate only the strains that hold
the highest potential in producing novel enediyne natural
products. To validate the utility of the selected genes within the
enediyne PKS cassette as a beacon to search for new enediyne
producers from a large strain collection, we carried out a virtual
survey of the entire GenBank, using each of the ﬁve genes within
the enediyne PKS cassette, alone or in combination, as queries,
for genes encoding enediyne biosynthetic machineries. We were
able to identify all 10 conﬁrmed enediyne biosynthetic machiner-
ies (Fig. 2A), validating the utility and speciﬁcity of the genes
within the enediyne PKS cassette as probes. While each of the ﬁve
genes alone yields essentially the same outputs, E5, E, or E10 are
preferred, and the combination of E5/E or E/E10 afford the most
speciﬁc results. Most signiﬁcantly, we identiﬁed 51 additional
enediyne PKS cassettes from 47 organisms (four strains contain
two enediyne PKS cassettes each) not known as enediyne produc-
ers. Together with the 10 known enediyne biosynthetic machiner-
ies, the 61 total enediyne PKS cassettes support our early ﬁndings
that the biosynthetic potential of enediynes is signiﬁcantly under-
appreciated37,38 (i.e., a total of 61 enediyne biosynthetic gene clus-
ters from the GenBank database as of September 23, 2014). All of
the 61 gene clusters are of bacterial origin (out of 4889), and most
strikingly, 54 of the 61 clusters are in the order of Actinomycetales
(out of 796). While the Actinomycetales are well known as the
B. Shen et al. / Bioorg. Med. Chem. Lett. 25 (2015) 9–15 13
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lites,56 this is the ﬁrst time revealing the Actinomycetales as the
most proliﬁc producers of enediyne natural products.
Enediyne structural diversity as predicted by microbial genomics.
The new enediyne biosynthetic gene clusters can be readily differ-
entiated from the known ones upon phylogenetic analysis on the
basis of the enediyne PKS cassettes. As exempliﬁed by the phyloge-
netic analysis in Figure 3A, which is based on the amino acid
sequences of the E enzymes, the 10 known enediyne PKS cassettes
are well dispersed, and the 51 newly identiﬁed enediyne PKS cas-
settes are distinct from the 10 known enediyne PKS cassettes. Most
signiﬁcantly, many of the new enediyne PKS cassettes fell into
clades that were not represented by any of the 10 known enediyne
natural products, a provocative suggestion for novel enediyne
structures (Fig. 3A).
While the hallmark nine- or 10-membered enediyne cores are
essential for their phenomenal cytotoxicity, the enediyne natural
products are rich in peripheral moieties, and it is the diverse
peripheral chemistry displayed for each of the enediyne natural
products that ﬁne-tunes their biological activities. We have anno-
tated the 51 new enediyne gene clusters, though the boundaries of
the clusters are hypothetical, and they appear to be true enediyne
biosynthetic clusters, based on features common to the biosynthe-
sis of the known enediynes. As highlighted in Figure 3B, all the
clusters feature the conserved enediyne PKS cassettes indicating
the hosts are true enediyne producers, and the gene clusters are
rich in other open reading frames that are unprecedented in gene
clusters that encode the production of the known enediyne natural
products. The extraordinary number of novel open reading frames
is indicative of novel structural features and peripheral moieties,
which holds promise for the discovery of new enediyne natural
products.
Conclusions and prospects. Given the extreme potencies of the
enediyne family of natural products,1–6 their proven utility as cyto-
toxic payloads of anticancer ADCs, and the astonishing success rate
of these rare natural products in the clinic,7–12 the discovery of new
enediynes, as well as alternative producers of known enediynes
with high titers or better growth characteristics, is a critical step
in the development of enediynes as novel anticancer drugs. Thor-
ough bioinformatics analysis of microbial genomes reveals that
enediyne natural product gene clusters are widely distributed
among Actinomycetales (50 out of 796 sequenced bacterial gen-
omes, accounting for 6.3%), and yet remain underexplored, as the
newly identiﬁed gene clusters are non-redundant and highly
unique.37,38 The abundant and highly diverse enediyne gene clus-
ters found within public databases should provoke the interests
of scientiﬁc communities in pursuing novel enediyne natural
products from microbial strain collections, in particular from
Actinomycetales.
Combining traditional natural product discovery methods with
genomics-based technologies and bioinformatics will expedite the
discovery process of novel enediynes. High-throughput methods to
rapidly screen a large microbial strain collection for the conserved
genes within the enediyne PKS cassettes are essential to allocate
resources to strains that show biosynthetic potential for enediyne
production.48,49 DNA sequencing of the conserved pksE genes or
alternatively, the whole genome, allows further prioritization byFigure 3. Exploration of microbial genomics to discover new enediyne natural products.
acid sequences of Es, from the 49 putative enediyne gene clusters (two Es excluded due
and alignment of 44 new enediyne gene clusters, as well as seven additional enediyne P
clusters feature the conserved enediyne PKS cassette (highlighted in red), they also posse
that encode production of the known enediynes, indicative of novel structural features an
producers (i.e., 47 new producers with four containing two enediyne clusters each and th
(d) enediyne PKS cassettes only, and GenBank accession numbers for the new enediyne
3identifying redundant or unique enediyne biosynthetic gene clus-
ters through bioinformatics analysis (i.e., phylogenetic analysis,
cluster annotation, genome neighborhood network).37,38 Once
strains are prioritized, fermentation in multiple media and prepa-
ration of crude extracts allow chemical proﬁling of heptaene pro-
duction,46,47 and bioassays for DNA damage activity (i.e., by
BIA)37,50 can then be utilized to determine which strains readily
produce enediynes or enediyne-like metabolites. Fractionation of
promising crude extracts guided by the BIA allows a simple detec-
tion method for isolating novel enediynes. With the conserved
enediyne PKS gene cassettes known, DpksE deletion mutants can
be easily constructed to correlate putative gene clusters with the
production of heptaene or DNA-damaging natural products. Silent
or cryptic gene clusters can be overcome by the genetic manipula-
tion of positive or negative regulators found within the enediyne
gene clusters or by extensive fermentation optimization.35,36 The
expedient technologies and tools of recombinant DNA work in
Streptomyces species and related actinomycetes that have been
developed in the past two decades surely will facilitate these
efforts.
It is evident from the rarity of known enediyne natural products
that future enediyne discovery efforts must be approached using
new and innovative means.37,38 The advancement of DNA sequenc-
ing technologies and genomics-based approaches in recent years
has opened the door for a multi-disciplinary approach towards
the discovery of natural products and enediynes in particular.52,53
The potential of the enediynes as relevant clinical drugs and the
unique chemistry and enzymology involved in their biosynthesis
should be of great interest to cancer biologists, natural product
chemists, biochemists, enzymologists, structural biologists, and
the community as a whole. We are optimistic that enediynes will
continue to play an important role in natural product biosynthesis,
engineering, and drug discovery.
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